Product Description
Bosutinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells), including treatment in adults who have been recently found to have this condition and in those who can no longer benefit from other medications for CML or who cannot take these medications because of side effects. Bosutinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a613005.html)
Mechanisms of Action: Bcr-Abl Inhibitor,SRC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: Chronic Leukemia | Chronic Myeloid Leukemia | Leukemia | Myeloid Leukemia
Known Adverse Events: Abdominal Pain | Pain Unspecified | Anemia | Thrombocytopenia | Diarrhea
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Japan, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Chronic Myeloid Leukemia
Phase 2: Amyotrophic Lateral Sclerosis|Blast Crisis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloid, Accelerated Leukemia
Phase 1: Breast Cancer|Cognitive Dysfunction|Dementia|Healthy Volunteers|Malnutrition
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BosuPeg | P2 |
Active, not recruiting |
Chronic Myeloid Leukemia |
2028-12-12 |
|
| AAML1921 | P2 |
Active, not recruiting |
Blast Crisis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Myeloid, Accelerated Leukemia |
2028-07-01 |
|
| JapicCTI-183939 | P3 |
Active |
Chronic Myeloid Leukemia |
2024-06-01 |
|
| WI240618 | P2 |
Recruiting |
Amyotrophic Lateral Sclerosis |
2024-03-31 |